Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.
A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results